PepLib Information

Zonsen PepLib Biotech Inc. is an innovative biotechnology company dedicated to the discovery and development of novel peptide-based therapeutics aimed at improving treatment options for patients worldwide. Founded in September 2017, PepLib is headquartered in Zhuzhou, China, with operations in Changsha, China, and a subsidiary in New Jersey, USA. PepLib employs more than 200 people, over 80% of whom are engaged in research and development. PepLib closed its Series A financing round of CNY 100 million in December 2019, followed by a Series A+ financing round of CNY 220 million in April 2021, then secured nearly CNY 100 million through its Series B financing round in July 2025.Most recently, a Series C financing round of over CNY 300 million was completed in May 2026. To date, PepLib has secured research and development (R&D) collaboration agreements with leading pharmaceutical enterprises, including Novartis, Eli Lilly, AstraZeneca, among others. PepLib has established a robust and diverse suite of proprietary peptide libraries and discovery capabilities, with a primary therapeutic focus in oncology and cardiometabolic diseases. PepLib’s platforms support multiple peptide-based modalities, including peptide radionuclide conjugates (PRCs), peptide oligonucleotide conjugates (POCs), and peptide drug conjugates (PDCs).